Cargando…
Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
BACKGROUND: The epidermal growth factor receptor (EGFR) inhibitors represent the first-line therapy regimen for non-small cell lung cancer (NSCLC). Most of these inhibitors target the ATP-site to stop the aggressive development of NSCLC. Stabilization of the ATP-binding on EGFR is difficult due to a...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381467/ https://www.ncbi.nlm.nih.gov/pubmed/32666476 http://dx.doi.org/10.1007/s43440-020-00131-0 |